Elevated Circulating Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Levels Are Associated With Neuroendocrine Differentiation in Castration Resistant Prostate Cancer

被引:22
作者
Gong, Yixuan [1 ]
Chippada-Venkata, Uma D. [1 ]
Galsky, Matthew D. [1 ]
Huang, Jiaoti [2 ]
Oh, William K. [1 ]
机构
[1] Mt Sinai Sch Med, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY 10029 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
关键词
TIMP-1; prostate cancer; neuroendocrine differentiation; castration resistance; NEURON-SPECIFIC ENOLASE; SMALL-CELL CARCINOMA; LONG-TERM SURVIVAL; CHROMOGRANIN-A; COLORECTAL-CANCER; PROGNOSTIC ROLE; GROWTH-FACTOR; TUMOR-GROWTH; EXPRESSION; INTERLEUKIN-6;
D O I
10.1002/pros.22945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUNDTissue inhibitor of metalloproteinase-1 (TIMP-1) is a 28.5kDa secreted glycoprotein that inhibits matrix metalloproteinase (MMP) activity. Our group has previously shown that elevated plasma TIMP-1 levels predict poor survival in metastatic castration-resistant prostate cancer (CRPC) patients; however, the underlying source and impact of elevated circulating TIMP-1 protein is unknown. METHODSIn this study, we used qRT-PCR, ELISA and immunohistochemistry to evaluate TIMP-1 expression in androgen-sensitive and resistant prostate cancer (PC) cell lines, tumor tissues and patient sera, and to correlate TIMP-1 levels to expression of chromogranin A (CGA), an established marker of neuroendocrine differentiation (NED). We also explored the relationship between TIMP-1 overexpression and induction of NED by overexpressing TIMP-1 in androgen-sensitive LNCaP cells, as well as by inducing NED of LNCaP cells with IL-6. RESULTSPatients with CRPC have significantly higher serum TIMP-1 levels compared to patients with hormone-sensitive disease. Although circulating TIMP-1 levels were increased, peripheral blood cells were not the source of elevation. Instead, elevated TIMP-1 expression was associated with higher expression of CGA in both blood and metastatic tumor tissue. We further show that androgen receptor (AR) and PSA non-expressing prostate cancer cell lines known to display NED phenotypes such as PC-3, PC-3M, and DU145 cells, expressed high levels of TIMP-1, in contrast to AR (+) and PSA (+) adenocarcinoma cell lines such as LNCaP, VCaP, and LAPC-4, which had barely detectable levels of TIMP-1. In addition, ectopic overexpression of TIMP-1 in LNCaP cells did not induce NED. However, TIMP-1 mRNA expression was elevated >10-fold during IL-6-induced NED of LNCaP cells, suggesting that TIMP-1 overexpression accompanies, but is not the driving force for NED. Finally, we show that conditioned media from androgen-resistant PC-3, PC-3M, and DU145 cells induced TIMP-1 mRNA expression in primary prostate stromal fibroblasts in an ERK and NF-B dependent manner. CONCLUSIONSWe provide in vitro and clinical evidence to support the association between NED and elevated circulating TIMP-1 expression in CRPC. Our observation supports further evaluation of TIMP-1 as a tissue and serum biomarker for NED in CRPC. Prostate 75: 616-627, 2015. (c) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:616 / 627
页数:12
相关论文
共 56 条
  • [1] High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome
    Aldulaymi, Bahir
    Bystrom, Per
    Berglund, Ake
    Christensen, Ib J.
    Brunner, Nils
    Nielsen, Hans J.
    Glimelius, Bengt
    [J]. ONCOLOGY, 2010, 79 (1-2) : 144 - 149
  • [2] [Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590
  • [3] Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
    Baudin, E
    Gigliotti, A
    Ducreux, R
    Ropers, J
    Comoy, E
    Sabourin, JC
    Bidart, JM
    Cailleux, AF
    Bonacci, R
    Ruffié, P
    Schlumberger, M
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (08) : 1102 - 1107
  • [4] Bellmunt Joaquim, 2010, Ther Adv Med Oncol, V2, P189, DOI 10.1177/1758834009359769
  • [5] Beltran H, 2013, J CLIN ONCOL S, P31
  • [6] Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
    Beltran, Himisha
    Tagawa, Scott T.
    Park, Kyung
    MacDonald, Theresa
    Milowsky, Matthew I.
    Mosquera, Juan Miguel
    Rubin, Mark A.
    Nanus, David M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) : E386 - E389
  • [7] Plasma chromogranin A in incidental non-functioning, benign, solid adrenocortical tumors
    Bernini, G
    Moretti, A
    Fontana, V
    Orlandini, C
    Miccoli, P
    Berti, P
    Basolo, F
    Faviana, P
    Bardini, M
    Salvetti, A
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 151 (02) : 215 - 222
  • [8] Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
    Berruti, A
    Mosca, A
    Tucci, M
    Terrone, C
    Torta, M
    Tarabuzzi, R
    Russo, L
    Cracco, C
    Bollito, E
    Scarpa, RM
    Angeli, A
    Dogliotti, L
    [J]. ENDOCRINE-RELATED CANCER, 2005, 12 (01) : 109 - 117
  • [9] The Prognostic Role of Immunohistochemical Chromogranin A Expression in Prostate Cancer Patients Is Significantly Modified by Androgen-Deprivation Therapy
    Berruti, Alfredo
    Bollito, Enrico
    Cracco, Cecilia M.
    Volante, Marco
    Ciccone, Giovannino
    Porpiglia, Francesco
    Papotti, Mauro
    Scarpa, Roberto Mario
    Dogliotti, Luigi
    [J]. PROSTATE, 2010, 70 (07) : 718 - 726
  • [10] TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro
    Bigelow, Rebecca L. H.
    Williams, Briana J.
    Carroll, Jennifer L.
    Daves, Lisa K.
    Cardelli, James A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (01) : 31 - 44